Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PPIB | P23284 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29133215 | 0.76 | MAOA (0.45) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL754484 | 0.73 | MAOA (0.38) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL21248511 | 0.73 | MAOB (0.38) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL29798795 | 0.72 | MAOA (0.43) | MAOAMAOBCYP2C9POLBL3MBTL1 | |
| SCHEMBL7783926 | 0.72 | MAOA (0.43) | MAOAMAOBCYP2C9POLBL3MBTL1 | |
| SCHEMBL31653943 | 0.71 | MAOA (0.35) | MAOAMAOBPPIBHTR2AHRH1 | |
| SCHEMBL8934572 | 0.70 | HTT (0.42) | PPIBL3MBTL1MEN1KMT2A | |
| SCHEMBL31015957 | 0.68 | MAOA (0.43) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL28616256 | 0.68 | MAOA (0.43) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL3679517 | 0.68 | CYP2C9 (0.35) | CYP2C9MEN1TSHRKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150770-A1 | METHODS OF TREATING SKIN | TRACIE MARTYN INTERNATIONAL INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140155961-A1 | METHODS OF TREATING SKIN | Tracie Martyn International, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20100272790-A1 | Methods of Treating Skin | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776915-B2 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7462478-B2 | isolated from licorice; catalyzes a dehydration reaction of 2-hydroxy hisoflavanone | NIHON UNIVERSITY (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155961-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | MAOA 334/4885MAOB 737/4885PPIB 1707/4885 |
| US-20100272790-A1 | Methods of Treating Skin | CUTA, LIPA, DLAT | MAOA 334/4885MAOB 737/4885PPIB 1707/4885 |
| US-20150150770-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | MAOA 334/4885MAOB 737/4885PPIB 1707/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | MAOA 314/4885MAOB 757/4885PPIB 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.